CTLA4-Ig Effectively Controls Clinical Deterioration and Immune Condition in a Murine Model of Foxp3 Deficiency.

J Clin Immunol · 2023 · PMC10354160 · PMID 37156988

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Aggregate clinical scores demonstrated a near-complete correction of pathology in CTLA4-Ig-treated mice, while rapamycin-treated mice exhibited a ~ 50% protection and anti-CD4 antibody-treated mice only a nonsignificant trend in protection (Fig. 2 B).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.